多靶点酪氨酸激酶抑制剂的潜在心脏毒性及其发生机制  

Potential cardiotoxicity and its mechanism of multi-target tyrosine kinase inhibitors

作　　者：韩森[1] 王一鸣[2] 王欢[2,3] Han Sen;Wang Yiming;Wang Huan(Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Peking University Cancer Hospital&Institute,Beijing 100142,China;Institute of Systems Biomedicine,Peking University,Beijing 100191,China;Department of Medical Bioinformatics,School of Basic Medical Sciences,Peking University Health Science Center,Beijing 100191,China)

机构地区：[1]北京大学肿瘤医院暨北京市肿瘤防治研究所,恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142 [2]北京大学系统生物医学研究所,北京100191 [3]北京大学医学部基础医学院医学生物信息系,北京100191

出　　处：《中华心力衰竭和心肌病杂志(中英文)》2024年第4期317-322,共6页Chinese Journal of Heart Failure and Cardiomyopathy

基　　金：国家自然科学基金委员会面上项目(881973403);北京市医院管理中心培育计划(PX2023040)。

摘　　要：多靶点酪氨酸激酶抑制剂(TKI)在肿瘤治疗中发挥重要作用,但是在抗肿瘤治疗的同时,其心脏毒性也逐渐显现出来,例如心功能不全/心力衰竭、心肌缺血/心肌梗死、高血压、QT间期延长等。本文将系统性阐述多靶点TKI的主要心脏毒性特点,以及索拉非尼、舒尼替尼、普纳替尼和安罗替尼等代表性药物所导致心脏毒性的发生机制,期望能有助于更好地预防、监测和治疗靶向药物诱导的心血管不良事件。Multi-target tyrosine kinase inhibitors(TKIs)play an important role in cancer therapy.However,while achieving anti-tumor therapeutic effects,their cardiotoxicity gradually emerged,such as cardiac insufficiency/heart failure,myocardial ischemia/myocardial infarction,hypertension and QT interval prolongation.This article systematically describes the main cardiotoxicity characteristics of multi-target TKIs(such as sorafenib,sunitinib,ponatinib and anlotinib),and their mechanism of cardiotoxicity.Understanding the cardiotoxic characteristics and potential mechanisms will help us to prevent,monitor and treat cardiovascular adverse events induced by those targeted drugs.

关 键 词：靶向治疗 酪氨酸激酶抑制剂 心脏毒性 肿瘤心脏病学 

分 类 号：R730.5[医药卫生—肿瘤]